Nyrada Inc Addresses ASX Price Query Following NYR Shares Jump from $0.41 to $0.535 on July 15, 2026

ASX Price Query Triggered by Nyrada’s Intraday Share Price Increase from $0.410 to $0.535 on 15 July 2026

On 15 July 2026, ASX Listings Compliance contacted Nyrada Inc’s Company Secretary, David Franks, requesting a formal explanation for a significant intraday price movement in NYR securities. The ASX noted that shares rose from an intraday low of $0.410 to a high of $0.535, coupled with a substantial surge in trading volume, prompting the query under Listing Rule 18.7.

The exchange sought answers regarding whether Nyrada was aware of any material, non-public information that could explain the trading, whether any exceptions under Listing Rule 3.1A applied, and confirmation of ongoing compliance with Listing Rule 3.1. The company was required to respond by 4:30 PM AEST on 15 July 2026, to which it complied within the stipulated timeframe.

Nyrada Confirms Absence of Undisclosed Information Behind NYR Trading Activity

In its formal response, Nyrada stated it is not aware of any material information that has not been publicly disclosed which could account for the recent trading activity. This affirmation aligns with ASX’s continuous disclosure requirements, indicating the company holds no undisclosed data influencing share price or volume.

Moreover, Nyrada indicated it has no alternative explanation for the price and volume changes, confirming no known corporate developments, sector events, or market commentary justify the movements. The response was authorised by CEO and Managing Director James Bonnar on behalf of the Board, fulfilling ASX Listing Rule 18.7 obligations.

CEO James Bonnar Reaffirms Nyrada’s Compliance with ASX Listing Rule 3.1

A critical element of the reply was Nyrada’s explicit confirmation of compliance with ASX Listing Rule 3.1, which mandates immediate disclosure of any information that could materially affect the price or value of securities unless exceptions under Rule 3.1A apply.

James Bonnar’s authorisation of the response underscores the company’s commitment to governance and regulatory transparency. Company Secretary David Franks, responsible for external compliance communications, signed the response letter. Nyrada’s registered office is Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000. Investor and media inquiries are managed by Dimitri Burshtein on behalf of the company.

Investor Focus on Xolatryp Phase IIa STEMI Trial as Key Catalyst for NYR

Investor interest in Nyrada is largely driven by its clinical-stage status and lead asset, Xolatryp4, a small-molecule therapy targeting TRPC ion channels. Xolatryp has demonstrated efficacy in preclinical models across cardioprotection, neuroprotection, and oncology, and has completed a Phase I first-in-human trial.

Currently, Nyrada is conducting a Phase IIa clinical trial evaluating Xolatryp’s safety and preliminary efficacy in mitigating cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing percutaneous coronary intervention (PCI). STEMI is a severe heart attack type, and reperfusion injury remains a critical clinical challenge without widely approved pharmacological treatments. This trial represents a significant milestone and is a major near-term focus for investors.

Nyrada’s Clinical-Stage Biotech Profile and TRPC Ion Channel Therapeutic Approach

Incorporated in Delaware, USA, with ARBN 625 401 818 in Australia, Nyrada is a clinical-stage biotech company listed on the ASX. It currently generates no commercial revenue, with value tied to clinical and regulatory progress of its pipeline, particularly Xolatryp4.

TRPC ion channels regulate ion flow across cell membranes and are implicated in diseases including cardiac injury, neurological disorders, and cancer. Nyrada’s small-molecule therapies aim to modulate these channels, offering potential across multiple therapeutic areas. Xolatryp’s broad preclinical efficacy supports a platform approach beyond a single indication.

Understanding ASX Price Query Mechanism and Implications for NYR Investors

The ASX price query process is a standard market surveillance tool used when unusual price or volume changes lack apparent public explanation. Under Listing Rule 18.7, the ASX requests clarification to ensure all investors have equal access to material information.

If undisclosed material information exists, companies must immediately release it or request a trading halt. Nyrada’s confirmation of no undisclosed information means trading continues normally. For NYR shareholders, this response provides regulatory transparency, confirming no material information was withheld at the time. Such unexplained trading activity is common in smaller biotech stocks due to market speculation and sentiment.

Risk Considerations for Nyrada as a Pre-Revenue Clinical-Stage Biotech

Potential investors should recognise the high-risk nature of Nyrada’s business model. As a clinical-stage biotech without commercial revenue, its future depends heavily on successful clinical trial progression, regulatory approvals, and scientific outcomes, all of which carry significant uncertainty.

Clinical trials, including the ongoing Phase IIa STEMI study, may encounter delays, fail endpoints, or produce unexpected results, potentially impacting share price and capital raising ability. Nyrada’s forward-looking statements caution that actual results may differ materially due to known and unknown risks, including external factors like the COVID-19 pandemic. Investors in such companies face binary risk events linked to clinical data releases.

No Additional Corporate Updates Released with Nyrada’s ASX Price Query Response

The 15 July 2026 company update was limited to the formal price query response. No new announcements regarding the Phase IIa trial, interim results, partnerships, capital raises, or other developments accompanied the response. Consequently, investors have no new material information beyond prior disclosures.

The next significant milestone for shareholders will likely be clinical data updates from the Phase IIa STEMI trial, which would be material and subject to immediate market release. No timeline for such updates was provided in the current communication.

Governance and Authorisation Behind Nyrada’s Price Query Response

The formal response was signed by Company Secretary David Franks and authorised by CEO and Managing Director James Bonnar on behalf of the Board. This dual approval meets ASX governance standards, ensuring senior executive accountability for disclosures.

James Bonnar’s dual role as CEO and Managing Director places him at the helm of Nyrada’s strategic and regulatory compliance efforts. His direct involvement in authorising the response highlights the importance of continuous disclosure obligations. Investor and media contacts for Nyrada are Dimitri Burshtein ([email protected], 0491 789 391), while Company Secretary queries are handled by David Franks via the Automic Group ([email protected], 02 8072 1400).